plumonary arterial hypertension
Conditions
Interventions
Nicardipine was administered by short-time continuous infusion (1 microg/kg/min for 5 min and 2 microg/kg/min for 5 min) followed by bolus injection (5 microg/kg). Hemodynamic responses were continuou
Sponsors
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
National Hospital Organization, Okayama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed as having PAH without left heart disease PAH is defined by a resting mean pulmonary artery pressure (PAP) 25 mmHg and more during right heart catheterization (RHC) with a mean pulmonary capillary wedge pressure (PCWP) 15 mmHg and less.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: thromboembolic pulmonary hypertension, hemodynamic instability including cardiac index less than 2.2 L/min/m2 and systolic blood pressure less than 80mmHg, or having symptoms associated with low cardiac output at rest.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety of acute vasoreactivity testing with nicardipine in PAH patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Whether can acute vasoreactivity testing with nicardipine identify patients with sustained beneficial response to oral calcium channel blockers. | — |
Countries
Japan
Contacts
Public ContactNakamura Kazufumi
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Department of Cardiovascular Medicine
Outcome results
None listed